Purple Biotech issues letter to shareholders from CEO

Purple Biotech (PPBT) issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company’s scientific progress, operational execution, and strategic milestones during the first half of 2025. “I am pleased to report that the first half of 2025 has been marked by meaningful scientific advancements across all of our core programs, prudent financial management, and continued investor support. Despite a challenging market environment, our team remained focused on delivering value-creating data and positioning Purple Biotech for anticipated upcoming catalysts… Upcoming Catalysts: Plan to advance CM24 into a biomarker-driven Phase 2b study in second-line PDAC targeting approximately 165 patients; Targeting investigational new drug application submission to the U.S. Food and Drug Administration for the first development candidate from our novel CAPTN-3 platform in 2026, with plans to initiate first-in-human trials following IND approval; Expect to generate interim NT219 Phase 2 data in 2026, alongside new preclinical data for next-generation assets. We maintained disciplined cash management in the first half of 2025, and currently expect our financial runway to extend into mid-2026. Additional funding will be required to support the execution of future clinical studies.”